BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Clinical trials for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) explained in plain language.
Never miss a new study
Get alerted when new BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) trials appear
Sign up with your email to follow new studies for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on relapsed blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a personalized cell therapy called CART123 for adults with certain blood cancers (like acute myeloid leukemia) that have not responded to standard treatments. Each patient's own immune cells are modified in a lab to target and attack cancer cells. The…
Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Rare cancer registry aims to unlock treatment secrets
Knowledge-focused Recruiting nowThis study is creating a worldwide database for a very rare blood cancer called BPDCN. Researchers will collect information from about 200 patients to understand how the disease behaves and which treatments work best. The goal is to use this knowledge to develop better treatment …
Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Sponsor: Immune Oncology Research Institute • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC